低分子肝素治疗原发性肾小球肾炎的临床探讨

Clinical Study of Low Molecular Weight Heparin in Treatment of Primary Glomerulonephritis

目的探讨在治疗原发性肾小球肾炎过程中使用低分子肝素的效果。方法整理收集2014年3月~2016年5月我院治疗的原发性肾小球肾炎患者88例,对比组44例患者提供洛汀新和强的松治疗方案;研究组44例则在对比组治疗方案基础上联合使用低分子肝素。结果研究组患者内生肌酐清除率为明显低于对比组,同时研究组尿蛋白、血清白蛋白含量均低于对比组;血尿素氮、肌酐则高于对比组,差异有统计学意义（P〈0.05）。结论利用低分子肝素治疗原发性肾小球肾炎可以有效改善肾脏功能,降低损伤情况。

Objective To investigate the effect of low molecular weight heparin in the treatment of primary glomerulonephritis. Methods Collect from March 2014 to May 2016 in our hospital 88 cases of patients with primary glomerulonephritis,contrast group of 44 patients with Lotensin and prednisone treatment,study group of 44 cases in the contrast group treatment based on the combined use of low molecular weight heparin. Results Patients in the study group,the endogenous creatinine clearance rate was significantly lower than the comparison group,the study group of urine protein,serum albumin levels were lower than the contrast group; blood urea nitrogen and creatinine were higher than the comparison group,the difference was statistically significant（P〈0.05）. Conclusion Low molecular weight heparin in the treatment of primary glomerulonephritis can effectively improve renal function,reduce injury.